Indium (111in) Dtpa Curium Netherlands B.V

Indium-111 pentetate, the active ingredient in Indium (111in) Dtpa Curium Netherlands B.V, is a radiopharmaceutical presented as a sterile solution for intrathecal use. It enables gamma‑emitting imaging of cerebrospinal fluid pathways for diagnostic purposes. GNH USA supplies Indium (111in) Dtpa Curium Netherlands B.V as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Indium-111 pentetate is used in diagnostic imaging of the cerebrospinal fluid system and related studies. - Cerebrospinal fluid pathway imaging: enables visualization of CSF flow and compartments using gamma‑camera techniques. - CSF leak detection: highlights tracer extravasation to locate cerebrospinal fluid leaks. - Intrathecal radioisotope studies: supports quantitative assessment of CSF dynamics and distribution after intrathecal administration.

Adverse reactions may occur following intrathecal administration of Indium-111 pentetate.

Common Side Effects: - Headache: mild to moderate pain often transient after injection. - Nausea: occasional feeling of queasiness. - Transient back pain: discomfort at the lumbar puncture site. - Mild fever: low‑grade temperature rise. - Local irritation: redness or mild swelling at injection site. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or anaphylaxis. - Seizure: rare neurologic event. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced myelopathy: delayed spinal cord injury. - Hemorrhage: spinal or subarachnoid bleeding. - Infection: meningitis or localized infection at puncture site.

Careful consideration is required before using Indium-111 pentetate. - Pregnancy: safety unknown; avoid unless essential. - Breastfeeding: safety unknown; weigh potential risks. - Renal impairment: monitor because clearance may be reduced. - Allergy to DTPA: contraindicated in known hypersensitivity. - Radiation safety: limit occupational exposure and follow shielding protocols. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated prior to administration.

Major Interactions (Avoid): - Concurrent intrathecal radiopharmaceuticals: additive radiation dose. - High‑dose iodinated contrast agents: may interfere with imaging quality. - Myelosuppressive chemotherapy: increased risk of radiation toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for spinal bleeding. - Corticosteroids: may alter CSF dynamics. - Neurotoxic drugs: observe for additive neurotoxicity.